Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Alonso-Coello

Showing results (351-360 of 387) with videos related to

Pageof 39
Sort By:
Trials|October 18, 2013
Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study designGabriela J Prutsky, Juan Pablo Domecq, Patricia J Erwin, et al.
Health and Quality of Life Outcomes|May 3, 2017
Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approachYuan Zhang, Pablo Alonso Coello, Jan Brożek, et al.
Journal of Clinical Epidemiology|August 7, 2022
GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisionsHolger J Schünemann, Ignacio Neumann, Monica Hultcrantz, et al.
Allergy|March 24, 2023
Is exposure to pollen a risk factor for moderate and severe asthma exacerbations?Isabella Annesi-Maesano, Lorenzo Cecchi, Benedetta Biagioni, et al.
Journal of Clinical Epidemiology|November 13, 2015
Systematic reviews experience major limitations in reporting absolute effectsPablo Alonso-Coello, Alonso Carrasco-Labra, Romina Brignardello-Petersen, et al.
Journal of Clinical Epidemiology|August 25, 2016
Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstractsArnav Agarwal, Bradley C Johnston, Robin W M Vernooij, et al.
Allergy|February 9, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Jessica Beltran, Cezmi Akdis, et al.
Allergy|March 11, 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaIoana Agache, Yang Song, Claudio Rocha, et al.
Systematic Reviews|December 17, 2013
A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocolPablo Alonso-Coello, Alonso Carrasco-Labra, Romina Brignardello-Petersen, et al.
Allergy|February 18, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Claudio Rocha, Jessica Beltran, et al.
Pageof 39

Showing results (351-360 of 387) with videos related to

Sort By:
Pageof 39
Trials|October 18, 2013
Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study designGabriela J Prutsky, Juan Pablo Domecq, Patricia J Erwin, et al.
Health and Quality of Life Outcomes|May 3, 2017
Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approachYuan Zhang, Pablo Alonso Coello, Jan Brożek, et al.
Journal of Clinical Epidemiology|August 7, 2022
GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisionsHolger J Schünemann, Ignacio Neumann, Monica Hultcrantz, et al.
Allergy|March 24, 2023
Is exposure to pollen a risk factor for moderate and severe asthma exacerbations?Isabella Annesi-Maesano, Lorenzo Cecchi, Benedetta Biagioni, et al.
Journal of Clinical Epidemiology|November 13, 2015
Systematic reviews experience major limitations in reporting absolute effectsPablo Alonso-Coello, Alonso Carrasco-Labra, Romina Brignardello-Petersen, et al.
Journal of Clinical Epidemiology|August 25, 2016
Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstractsArnav Agarwal, Bradley C Johnston, Robin W M Vernooij, et al.
Allergy|February 9, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Jessica Beltran, Cezmi Akdis, et al.
Allergy|March 11, 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaIoana Agache, Yang Song, Claudio Rocha, et al.
Systematic Reviews|December 17, 2013
A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocolPablo Alonso-Coello, Alonso Carrasco-Labra, Romina Brignardello-Petersen, et al.
Allergy|February 18, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Claudio Rocha, Jessica Beltran, et al.
Pageof 39